Testing an immune memory boost with checkpoint therapy
Part of Cancer, Skin clinical trials.
This early study tests whether “immune recall” (training the immune system using specific vaccine-like steps) can improve how well checkpoint drugs work for advanced melanoma. It is designed mainly to see if the approach is feasible and safe, and it may help some people respond better to PD-1 (with or without CTLA-4) treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have confirmed advanced melanoma that has spread (metastatic melanoma).
- You must be age 18 or older and able to sign (or have a representative sign) consent.
- Your cancer doctor must be planning you to receive PD-1 treatment, or PD-1 plus another checkpoint drug (CTLA-4), as standard care.
- You need at least one target spot/lesion that is at least 8 mm and can be examined or sampled with a biopsy (often ultrasound-guided).
- You must have recent blood count results that show: enough white blood cells, platelets, and hemoglobin.
- You cannot have certain melanoma types (uveal or mucosal), be pregnant or breastfeeding, or have had prior whole-body treatment for metastatic melanoma (prior surgery is okay).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at immune cells in your blood to find patterns that might show how well a treatment called anti-PD1 immunotherapy works for melanoma. Your participation could help doctors better understand who benefits from this therapy.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a new combination immunotherapy for people with advanced melanoma. It aims to help those whose cancer has not been controlled by standard treatments.
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
This trial tests a new treatment for advanced melanoma that can be surgically removed. It combines your own immune cells (called gamma-delta T cells) with a drug (interferon or a PD-1 blocker) to see if it helps the body fight the cancer before and after surgery.
This study tests whether giving immunotherapy (medicines that help your immune system fight cancer) at specific times of day—aligned with your body's natural rhythms—works better for advanced melanoma. Researchers will randomly assign you to receive treatment either on a timed schedule or a standard schedule.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.